SOURCE: LifeSci Advisors

LifeSci Advisors

July 02, 2012 10:30 ET

LifeSci Advisors Publishes Lomitapide and Mipomersen Physician Survey Results

Survey Shows Strong Preference for Lomitapide Over Mipomersen; Available for Download at

NEW YORK, NY--(Marketwire - Jul 2, 2012) - LifeSci Advisors, LLC, a leading provider of investment research and investor relations services in the life sciences sector, today announced that it has published an independent survey of 39 practicing lipidologists who answered on their expected use of Aegerion Pharmaceuticals' lomitapide and Isis Pharmaceuticals' mipomersen in patients with Homozygous Familial Hypercholesterolemia (HoFH) or "uncontrollably" high LDL levels, should these two new drugs get approved by the FDA.

"Based on the results of our proprietary survey of lipidologists, we believe there is much stronger interest in the use of lomitapide over mipomersen for the treatment of patients with extremely high and uncontrollable cholesterol levels," said Andrew I. McDonald, Ph.D., Founding Partner at LifeSci Advisors. "The 39 survey responders intend to prescribe lomitapide to a total of 254 patients and mipomersen to a total of 152 patients. "Regarding efficacy, 44% of the responders view lomitapide as very efficacious compared to 13% for mipomersen. Regarding safety, 62% of the responders view lomitapide as moderately safe compared to 43% for mipomersen."

Lomitapide, a microsomal triglyceride protein inhibitor, is a once-daily pill being developed by Aegerion Pharmaceuticals for the HoFH indication. It has a PDUFA data of December 29, 2012. Aegerion holds exclusive worldwide rights to lomitapide. Mipomersen is an apolipoprotein-B (apo-B) synthesis inhibitor co-developed by Isis and Genzyme, which has a January 29, 2013 PDUFA date for the HoFH indication.

Dr. McDonald's full Survey Report is available to download at no cost at the LifeSci Advisors website,

The LifeSci Advisors research team is led by Dr. Andrew I. McDonald, an industry veteran with more than 15 years of healthcare industry experience. Prior to co-founding LSA, Dr. McDonald was the Senior Biotechnology Analyst at Great Point Partners, a leading health care investment firm with over $500 million under management. Before Great Point, he was Co-Head of Healthcare Research and Lead Biotechnology Analyst at ThinkEquity Partners, a boutique investment banking firm focused on growth companies. Dr. McDonald holds a Ph.D. in organic chemistry from the University of California, Irvine, and, earlier in his career, worked as a medicinal chemist at both Pfizer and Cytokinetics.

About LifeSci Advisors:
LifeSci Advisors (LSA) is a leading research firm and communications consultancy dedicated to the life sciences industry. The firm provides strategic counsel, customized marketing communications, comprehensive research reports and investor relations services to companies that specialize in the discovery, development and commercialization of drugs, drug delivery systems, medical devices and diagnostics. To learn more about LSA, visit the company's website,

Important Disclosures:
The research report described in this press release is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell securities. The securities discussed in LSA research reports may be unsuitable for some investors depending on their specific investment objectives, financial status, risk profile, or particular needs. Investors should consider LSA reports as only a single source of information in making their investment decisions and should not rely solely on these reports in evaluating whether or not to buy or sell the securities of the subject company. LifeSci Advisors has not been compensated by the companies, including Aegerion Pharmaceuticals and Isis Pharmaceuticals, that are the subject of the report described. Please read each report's full disclosures and analyst background on the LSA website,, before investing. LifeSci Advisors is not a registered investment adviser or broker-dealer.

Forward-looking statements:
This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. These forward-looking statements represent LSA's judgment as of the date of this release. LifeSci Advisors disclaims, however, any intent or obligation to update these forward-looking statements.

Contact Information